|
2007 Announcements 19 Dec 2007
Foreign Shareholder Notice re Rights Issue
19 Dec 2007
Optionholder Notice re Rights Issue
19 Dec 2007
Shareholder Notice re Rights Issue
19 Dec 2007
Section 708AA Notice
19 Dec 2007
Appendix 3B - Non-renounceable Rights Issue
19 Dec 2007
Rights Issue NZ Investment Statement and Prospectus
19 Dec 2007
Rights Issue Letter of Offer
19 Dec 2007
D Clarke Appendix 3Z
19 Dec 2007
Neuren announces non-renounceable rights issue
4 Dec 2007
Neuren Clinical Development Update
3 Dec 2007
Neuren Corporate Update December 2007
12 Nov 2007
Neuren announces reorganisation
7 Nov 2007
NNZ-2566 successful Phase 1b trial results
31 Oct 2007
Appendix 4C - quarterly cash flows
16 Oct 2007
Neuren completes acquisition of Hamilton Pharmaceuticals
16 Oct 2007
Notice under section 708A(5)(e) of the Corporations Act
16 Oct 2007
Appendix 3B - issue of convertible notes
16 Oct 2007
Appendix 3B - issue of shares
15 Oct 2007
Neural Regeneration Peptides (NRP) update
12 Oct 2007
Results of Special Meeting
27 Sep 2007
Notice of Special Meeting of Shareholders
26 Sep 2007
Neuren launches Australian Phase 3 Trial Sites
20 Sep 2007
Neuren completes moderate TBI safety trial
7 Sep 2007
NZ arm of Phase 3 trial commences
31 Aug 2007
Interim Report 2007
31 Aug 2007
Appendix 4D
23 Aug 2007
Corporate Update Presentation
31 Jul 2007
Appendix 4C - quarterly cash flows
31 Jul 2007
Acquisition of MotivaTM through Hamilton Pharmaceuticals
24 Jul 2007
Lapse of Unquoted Options
29 Jun 2007
Cambridge University Alliance
31 May 2007
First patient enters Glypromate® Phase 3 trial
22 May 2007
Revised Constitution
22 May 2007
2007 AGM Results
22 May 2007
CEO Presentation to AGM
14 May 2007
Bachem Glypromate® Collaboration
10 May 2007
Clinical Trials Update May 2007
30 Apr 2007
Appendix 4C - quarterly cash flows
20 Apr 2007
Notice of Annual General Meeting
29 Mar 2007
Annual Report 2006
20 Mar 2007
Change of Director's Interest Notice
16 Mar 2007
Appendix 4E Preliminary Final Report
26 Feb 2007
Neuren scientist receives Laureate award
19 Feb 2007
Appendix 3B - ESOP options exercised
13 Feb 2007
Further Validation of NNZ-2566 as TBI Treatment
31 Jan 2007
Appendix 4C - quarterly cash flows
31 Jan 2007
US FDA approves Phase 3 IND for Glypromate® Trial
29 Jan 2007
Appendix 3B - escrow period ending 3 February 2007
17 Jan 2007
Appendix 3B
17 Jan 2007
Successful NNZ-2566 safety trial results
12 Jan 2007
CEO Presentation to Investors and Partners Jan 2007
|
